Genmab — September 2018
-
-
En lille artikel om EV fra januar i år, "Targeting AXL: a promising new strategy for tumor treatment" https://sparringbioconsult.com/targeting-axl-a-promising-new-strategy-for-tumor-treatment/
-
Enig med Peter i at EV er optaget af Enfortumab Vedotin. https://www.urotoday.com/conference-highlights/asco-2018/asco-2018-bladder-cancer/104867-asco-2018-updated-results-from-the-enfortumab-vedotin-phase-1-ev-101-study-in-patients-with-metastatic-urothelial-cancer.html
-
-
i think we all sort of missed this at ASCO...? http://abstracts.asco.org/214/AbstView_214_209799.html
-
Genmab er noget af en Jojo for tiden. Supplerede lidt igaar til 1065. Mon MAIA kommer i næste uge, tror det. Ved at være sidste udkald hvis man vil med paa næste store stigning. Kan simpelhen ikke forestille mig vi falder paa god MAIA data p.g.a den lave kurs p.t. Tror nærmere vi banker igennem 1400 inden udgang af September.
-
Linket virker stadigvæk ikke.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind